Pipeline

Advanced medicines that demonstrate both strong clinical performance and benefits to patients.

Pipeline
90
+
compounds, devices or indications in development individually or under collaboration or license agreement
investment
$7.1
b
R&D investment in 2022
Commitment
50
+
programs are in mid and late-stage development
Novel
60
%
of compounds in clinical development with a novel mechanism of action

Pipeline

Updated February 12, 2024

Sort By 
Focus Area
Molecule/Asset Phase
Molecule/Asset Type
Device Asset Phase
Device Asset Type
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hypothyroidism
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Parkinson's Disease
EU US
EU approved
US
approved
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Episodic Migraine Prophylaxis
N ∕ A
N ∕ A phase3
phase3
Essential Tremor
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
IC BPS
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease
US , EU
US , EU approved
approved
Psoriasis
US , EU
US , EU approved
approved
Psoriatic Arthritis
US , EU
US , EU approved
approved
Ulcerative Colitis
N ∕ A
N ∕ A
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Complicated Gram-negative Infections
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Systemic Lupus Erythematosus (SLE)
Global
Global phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alzheimer's Disease
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alzheimer's Disease
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Advanced Pancreatic Cancer
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Multiple Myeloma
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
COVID
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Open Angle Glaucoma
N ∕ A
N ∕ A phase2
phase2
Ocular Hypertension
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Multiple Myeloma
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Acute Lymphocytic Leukemia
N ∕ A
N ∕ A phase1
phase1
Acute Myeloid Leukemia
US , EU
US , EU approved
approved
Acute Myeloid Leukemia post transplant
N ∕ A
N ∕ A phase3
phase3
Chronic Lymphocytic Leukemia with 17p deletion
US , EU
US , EU approved
approved
First-line Chronic Lymphocytic Leukemia
US , EU
US , EU approved
approved
Myelodysplastic Syndrome
US , EU
US , EU phase3
phase3
Multiple Myeloma
N ∕ A
N ∕ A phase3
phase3
Relapsed ∕ Refractory Chronic Lymphocytic Leukemia
US , EU
US , EU approved
approved
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alzheimer's Disease
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ulcerative Colitis
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Non-Small Cell Lung Cancer
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Small Cell Lung Cancer
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Systemic Lupus Erythematosus (SLE)
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
IBD
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
wet AMD (subretinal)
N ∕ A
N ∕ A phase3
phase3
wet AMD (suprachoroidal)
N ∕ A
N ∕ A phase2
phase2
Diabetic Retinopathy (suprachoroidal)
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Amyotrophic Lateral Sclerosis (ALS)
N ∕ A
N ∕ A phase2
phase2
Vanishing White Matter disease (VWM)
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Glabellar Lines
N ∕ A
N ∕ A phase2
phase2
Forehead Lines
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Glabellar Lines
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Chronic Migraine Prophylaxis
US , EU
US , EU approved
approved
Episodic Migraine Prophylaxis
US , EU
US , EU approved
approved
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hidradenitis Suppurativa
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Platysma Prominence
N ∕ A
N ∕ A
Masseter Prominence
CN N ∕ A
CN
N ∕ A phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Follicular Lymphoma
US , EU
US , EU phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Bipolar Depression
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Atopic Dermatitis
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Diffuse Large B-cell Lymphoma
US , EU
US , EU approved
approved
Relapsed ∕ Refractory Follicular Lymphoma
N ∕ A
N ∕ A
First Line Follicular Lymphoma
N ∕ A
N ∕ A phase3
phase3
First Line Large B-cell Lymphoma
US , EU
US , EU phase3
phase3
B-cell Non-Hodgkin lymphoma
N ∕ A
N ∕ A phase2
phase2
Relapsed ∕ Refractory Chronic Lymphocytic Leukemia
N ∕ A
N ∕ A phase1
phase1
Richter's Syndrome
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Spinal Cord Injury
N ∕ A
N ∕ A phase2
phase2
Acute Ischemic Stroke
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alopecia Areata
N ∕ A
N ∕ A phase3
phase3
Ankylosing Spondylitis
US , EU
US , EU approved
approved
Atopic Dermatitis
US , EU
US , EU approved
approved
Axial SpA
US , EU
US , EU approved
approved
Crohn's Disease
US , EU
US , EU approved
approved
Giant Cell Arteritis
US , EU
US , EU phase3
phase3
Hidradenitis Suppurativa
N ∕ A
N ∕ A phase3
phase3
Psoriatic Arthritis
US , EU
US , EU approved
approved
Rheumatoid Arthritis
US , EU
US , EU approved
approved
Systemic Lupus Erythematosus (SLE)
N ∕ A
N ∕ A phase3
phase3
Takayasu Arteritis
JA
JA phase3
phase3
Ulcerative Colitis
US , EU
US , EU approved
approved
Vitiligo
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Liver
N ∕ A
N ∕ A phase2
phase2
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Colorectal Cancer
N ∕ A
N ∕ A phase2
phase2
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
HIV
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
BPDCN
N ∕ A
N ∕ A phase2
phase2
Acute Myeloid Leukemia
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ovarian Cancer
N ∕ A
N ∕ A phase1
phase1
Endometrial Cancer
N ∕ A
N ∕ A phase1
phase1
Other Fra-expressing cancers
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Platinum-Resistant Ovarian Cancer
N ∕ A
N ∕ A approved
approved
Platinum-Sensitive Ovarian Cancer
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Atrophic Scars
N A
N A confirmation
confirmation
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Facial Volume
EU N A
EU approved
N A development
approved
development
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Infraorbital Hollowing
US
US approved
approved
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Cellulite
N A
N A development
development
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Facial Volume
N A
N A confirmation
confirmation
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Fine Line Reduction
US , EU , JA
US , EU , JA approved
approved
Neck Line Reduction
N A
N A confirmation
confirmation
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Jawline Definition
US
US approved
approved
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Temple Augmentation
N A
N A confirmation
confirmation
No Results Found Change your filter or search criteria.